Brainstorm Posts 43% EPS Gain in Q2

Brainstorm Cell Therapeutics (OTC:BCLI), a biotechnology developer focused on neurodegenerative diseases, released its second quarter 2025 results on August 14, 2025. The headline news was a GAAP earnings per share was $0.34, beating analyst expectations of $(0.37) and improving from a loss of $0.60 in the prior year period. However, the company again posted no revenue as it remains pre-commercial. Most importantly, Brainstorm won clearance from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3b trial for its lead therapy, NurOwn, in amyotrophic lateral sclerosis (ALS). While the quarter showed progress on key clinical, regulatory, and operational fronts, a razor-thin cash balance and rising expenses put the company’s future plans at significant risk without near-term financing. Source: Analyst estimates for the quarter provided by FactSet. Brainstorm Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies to treat neurodegenerative conditions. Its core platform, NurOwn, is a cell therapy product targeting diseases like ALS and progressive multiple sclerosis (PMS).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool